Southworth Mary Ross
University of Illinois at Chicago, 840 S. Wood Street M/C 715, Chicago, IL 60612, USA.
Am J Health Syst Pharm. 2003 Aug 15;60 Suppl 4:S7-15. doi: 10.1093/ajhp/60.suppl_4.S7.
The benefits of nesiritide for the treatment of acute decompensated heart failure (ADHF) are discussed. In order to understand the goals of ADHF therapy, it is important to recognize the complex interplay between hemodynamic and neurohormonal abnormalities in patients suffering from heart failure. Goals of therapy include improvement in hemodynamic parameters, relief of symptoms, and minimization of adverse effects. Until recently, therapy with diuretics, positive inotropes, and intravenous vasodilators was the standard of care for treating ADHF. Nesiritide is the newest agent available for treating ADHF and may offer several benefits over standard of care therapy. It is important to remember that therapy for ADHF should not replace chronic oral heart failure therapy, nor should focus on prevention of ADHF episodes be lost.
探讨了奈西立肽治疗急性失代偿性心力衰竭(ADHF)的益处。为了理解ADHF治疗的目标,认识到心力衰竭患者血流动力学和神经激素异常之间复杂的相互作用很重要。治疗目标包括改善血流动力学参数、缓解症状以及将不良反应降至最低。直到最近,利尿剂、正性肌力药和静脉血管扩张剂治疗仍是治疗ADHF的标准治疗方法。奈西立肽是治疗ADHF的最新药物,可能比标准治疗方法有几个优势。重要的是要记住,ADHF治疗不应取代慢性口服心力衰竭治疗,也不应忽视对ADHF发作的预防。